Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
135.84
+0.29 (0.21%)
At close: Aug 14, 2026, 4:00 PM EDT
135.04
-0.80 (-0.59%)
After-hours: Aug 14, 2026, 7:56 PM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$887,587
Profits / Employee
$42,307
Market Cap
335.14B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
MRK News
- 2 days ago - Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials - Business Wire
- 4 days ago - Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences - CNBC
- 4 days ago - Merck price target raised to $145 from $130 at Argus - TheFly
- 5 days ago - Merck discloses 1.21M share holding in Evaxion Biotech - TheFly
- 8 days ago - These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks - Barrons
- 9 days ago - Merck says FDA accepts sBLA for enflonsia - TheFly
- 9 days ago - U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season - Business Wire
- 10 days ago - Merck announces Health Canada approval of KEYTRUDA for adults with MIBC - TheFly